BRIDGEBIO PHARMA INC (BBIO) Stock Income Statement
NASDAQ:BBIO - Nasdaq - US10806X1028 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 127.42M | 221.90M | 9.30M | 77.65M | 69.72M | |||
| Minority Interest Expense | 8.83M | 7.58M | 10.05M | 3.47M | 23.92M | |||
| Cost Of Goods | 5.92M | 3.88M | 2.45M | 3.43M | 3.11M | |||
| Gross Profit | 121.50M | 218.02M | 6.86M | 74.21M | 66.60M | |||
| Operating Expenses | 806.41M | 795.39M | 606.30M | 542.65M | 643.24M | |||
| Research and Development | 476.92M | 506.46M | 455.71M | 399.46M | 451.02M | |||
| Selling, General, and Administrative Expenses | 329.49M | 288.93M | 150.59M | 143.19M | 192.21M | |||
| Operating Income | -684.91M | -577.37M | -599.44M | -468.43M | -576.63M | |||
| Interest Income/Expense | -146.14M | -105.09M | -44.94M | 35.05M | -45.65M | |||
| Other Income/Expense | 11.02M | 4.14M | -944.00K | -7.50M | 35.82M | |||
| Non Recurring Items | 144.39M | 136.13M | -7.93M | -43.77M | N/A | |||
| Income Before Taxes | -675.64M | -542.19M | -653.25M | -484.65M | -586.45M | |||
| Income Tax | N/A | 1.15M | N/A | N/A | N/A | |||
| Net Income | -667.97M | -535.76M | -643.20M | -481.18M | -562.54M | |||
| EBITDA | -679.15M | -571.29M | -592.95M | -461.66M | -570.79M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.53 | -2.88 | -3.95 | -3.26 | -3.90 | |||
| Non GAAP EPS | -3.77 | -3.09 | -3.94 | -3.11 | -3.91 | |||
| Statistics | ||||||||
| Gross Profit Margin | 95.35% | 98.25% | 73.71% | 95.57% | 95.52% | |||
| Profit Margin | -524.25% | -241.44% | -6913.92% | -619.68% | -806.86% | |||
| Operating Profit Margin | -537.55% | -260.19% | -6443.56% | -603.26% | -827.07% | |||
All data in USD